Mitochondrial targeting and therapeutic use thereof
View Patent ↗The present invention provides, among other things, compositions and methods for treatment of Friedrich's Ataxia based on effective targeting of a therapeutic moiety to mitochondria that can substitute for natural FXN protein activity or rescue one or more phenotypes or symptoms associated with frataxin-deficiency. In some embodiments, the present invention provides a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus, a mitochondrial targeting sequence associated with the therapeutic moiety at the N-terminus, and a mitochondrial membrane-penetrating peptide associated with the therapeutic moiety at the C-terminus, wherein the therapeutic moiety is targeted to mitochondria upon cellular entry.
1. A method of targeting a therapeutic moiety to mitochondria, comprising contacting a cell with a targeted therapeutic comprising:
a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus and having an amino acid sequence at least 95% identical to the mature human Frataxin protein (SEQ ID NO: 1);
a mitochondrial targeting peptide fused at the N-terminus; and
a mitochondrial membrane-penetrating peptide fused at the C-terminus,
wherein the therapeutic moiety traffics to mitochondria upon cellular entry.
2. The method of claim 1 , wherein the mitochondrial targeting sequence peptide has an amino acid sequence at least 95% identical to SEQ ID NO:2.
3. The method of claim 1 , wherein the mitochondrial membrane-penetrating peptide has an amino acid sequence at least 95% identical to GYGRKKRRQRRR (SEQ ID NO:5).
4. The method of claim 1 , wherein the targeted therapeutic has an amino acid sequence at least 98% identical to SEQ ID NO:6.
5. A method of treating Friedreich's Ataxia comprising administering to a subject in need of treatment a targeted therapeutic comprising a therapeutic moiety, which is a polypeptide having an N-terminus and a C-terminus and having an amino acid sequence at least 95% identical to mature human frataxin protein (SEQ ID NO:1); wherein the therapeutic moiety comprises a mitochondrial targeting peptide fused at the N-terminus and a mitochondrial membrane-penetrating peptide fused at the C-terminus.
6. The method of claim 5 , wherein the mitochondrial targeting peptide has an amino acid sequence at least 95% identical to SEQ ID NO:2.
7. The method of claim 5 , wherein the mitochondrial membrane-penetrating peptide has an amino acid sequence at least 95% identical to GYGRKKRRQRRR (SEQ ID NO:5).